Citius Pharmaceuticals Inc. specialty pharmaceutical company. The Company develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. It has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)